December 17, 2024 - Regulatory SynAct Pharma AB publishes prospectus in connection with admission to trading of new shares on Nasdaq Stockholm
December 17, 2024 - Non-regulatory SynAct Pharma to join J.P. Morgan Healthcare Conference in San Francisco
November 27, 2024 - Non-regulatory SynAct Pharma receives EU trial approval for the Phase 2b ADVANCE study with resomelagon (AP1189)
November 20, 2024 - Regulatory SynAct Pharma intends to carry out directed issues totalling approximately 45 MSEK and a fully guaranteed rights issue totalling approximately 20 MSEK
November 14, 2024 - Non-regulatory SynAct Pharma presents positive clinical data on resomelagon (AP1189) supporting development for the treatment of RA at ACR Convergence
September 23, 2024 - Non-regulatory SynAct initiates the Phase 2b ADVANCE study with resomelagon (AP1189) in the US
September 13, 2024 - Non-regulatory SynAct Pharma to present clinical data on resomelagon (AP1189) at ACR Convergence
August 30, 2024 - Non-regulatory First scientific publication showing treatment potential of a pro-resolving compound in human virus infection
July 1, 2024 - Non-regulatory SynAct initiates filing process for Phase 2b ADVANCE study with resomelagon
April 23, 2024 - Regulatory Changes in SynAct Pharma’s Nomination Committee ahead of the 2024 Annual General Meeting
March 27, 2024 - Regulatory SynAct Pharma AB has successfully completed the bookbuilding procedure – directed issues provide the company with a total of up to 49.2 MSEK.
March 26, 2024 - Regulatory SynAct Pharma AB announces intention to carry out directed share issues in total of approximately 48 MSEK
March 25, 2024 - Regulatory SynAct Pharma AB (publ) (“SynAct”) brings forward the publication of the annual report.
March 10, 2024 - Regulatory SynAct Pharma announces outcomes of the independent audit of the 4-week RESOLVE P2a clinical trial in Rheumatoid Arthritis
February 23, 2024 - Regulatory SynAct Pharma AB (publ) (“SynAct”) today publishes the fourth quarter and annual results of 2023.
February 22, 2024 - Non-regulatory SynAct Pharma announces additional data from the EXPAND P2b clinical trial supporting continued development of the compound in rheumatoid arthritis
January 30, 2024 - Non-regulatory SynAct Pharma expands its Rheumatology Clinical Advisory Board with three new highly experienced advisors
January 28, 2024 - Regulatory The Board of Directors of SynAct Pharma AB has received a request to convene an EGM
